7 completed, 1 unknown. 8 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 7, Unknown 1 |
Follow bazedoxifene: new trials by email Literature Review of bazedoxifene trials Research Report on bazedoxifene
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Impact of Estrogen + Estradiol Receptor Alpha Modulator Therapy on Oxidative Stress in Post-menopausal Women With and Without Sleep Apnea Duavive (0.45 estrogens mg and 20 mg bazedoxifene) - Sleep Apnea, Post Menopausal | Phase 3 | Unknown | Laval University | 36 | 2019-11-01 | 2022-04-08 |
| Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis bazedoxifene 20 mg/ conjugated estrogens 0.45 mg, bazedoxifene 20 mg/ conjugated estrogens 0.625 mg, bazedoxifene 20 mg - Menopause, Osteoporosis | Phase 3 | Completed | Pfizer | 1886 | 2009-01-01 | 2014-04-08 |
| Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Symptoms Associated With Menopause Bazedoxifene/Conjugated Estrogen - Vasomotor Symptoms Associated With Menopause | Phase 3 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 325 | 2005-10-01 | 2007-12-28 |
| Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With Menopause Bazedoxifene/Conjugated Estrogen - Vaginal Atrophy | Phase 3 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 650 | 2005-10-01 | 2007-12-28 |
| Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women Bazedoxifene/Conjugated Estrogen, CE 0.45 mg/MPA 1.5mg, Placebo - Endometrial Hyperplasia, Osteoporosis | Phase 3 | Completed | Pfizer | 1083 | 2005-09-01 | 2013-12-20 |
| Study Evaluating Safety and Efficacy of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal Women Bazedoxifene/Conjugate Estrogens (CE), Raloxifene, Placebo - Endometrial Hyperplasia, Osteoporosis | Phase 3 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 3544 | 2002-04-01 | 2008-05-12 |
| Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women Bazedoxifene Acetate, Placebo - Osteoporosis | Phase 3 | Completed | Pfizer | 7609 | 2001-12-01 | 2013-04-10 |
| Study Evaluating TSE-424/Placebo/Raloxifene in Preventing Osteoporosis in Postmenopausal Women Bazedoxifene Acetate (TSE-424) - Osteoporosis | Phase 3 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 1742 | 2001-07-01 | 2009-08-21 |
Osteoporosis (5) · Endometrial Hyperplasia (2) · Osteoporosis, Postmenopausal (1) · Sleep Apnea Syndromes (1)
Wyeth is now a wholly owned subsidiary of Pfizer (4) · Pfizer (3) · Laval University (1)
United States (5) · Argentina (2) · Australia (2) · Canada (2) · Chile (2) · Denmark (2) · Finland (2) · Hungary (2) · Mexico (2) · New Zealand (2) · Norway (2) · Poland (2) · Austria (1) · Belgium (1) · Brazil (1)
PMID 27676118, PMID 19635615, PMID 20569451, PMID 23635731, PMID 24438370, PMID 28539177, PMID 37619252